Andrew Craig Miller - 16 Aug 2021 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role
Chief Operating Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
16 Aug 2021
Net transactions value
-$535,074
Form type
4
Filing time
18 Aug 2021, 19:44:10 UTC
Previous filing
14 Jun 2021
Next filing
03 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $36,500 +12,500 +27% $2.92* 58,000 16 Aug 2021 Direct
transaction KRTX Common Stock Sale $142,244 -1,379 -2.4% $103.15 56,621 16 Aug 2021 Direct F1, F2
transaction KRTX Common Stock Sale $418,747 -4,021 -7.1% $104.14 52,600 16 Aug 2021 Direct F1, F3
transaction KRTX Common Stock Sale $10,583 -100 -0.19% $105.83 52,500 16 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -12,500 -13% $0.000000 84,917 16 Aug 2021 Common Stock 12,500 $2.92 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.67 to $103.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.72 to $104.65, inclusive.
F4 This option vested as to 1/16th of the shares underlying the option award on the vesting commencement date of July 18, 2016 and as to an additional 1/16th of the shares on each three month anniversary thereafter.